<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759822</url>
  </required_header>
  <id_info>
    <org_study_id>CEMO/INCA-Haplo-01</org_study_id>
    <nct_id>NCT02759822</nct_id>
  </id_info>
  <brief_title>Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias</brief_title>
  <official_title>Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leonardo Javier Arcuri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancer, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective observational cohort study of haploidentical transplantation with
      post-transplant cyclophosphamide for acute leukemias using reduced intensity conditioning for
      acute myeloid leukemia (AML) and myeloablative conditioning for acute lymphoblastic leukemia
      (ALL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hematopoietic stem cell transplantation (HSCT) is the most effective treatment for acute
      myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), with the lowest rates of
      relapse.

      Fertility rate in Brazil is falling, and only 25% of people born today will have a matched
      sibling donor. On the other hand, currently donor non-related to about 50% of patients
      enrolled in Brazilian Receptor Registry (REREME). Consequently, at least 35% of patients
      won't have a matched donor.

      The haploidentical transplantation is defined as a partially matched hematopoietic cell
      transplantation, using a partially matched family donor (parent, sibling or child).
      Haploidentical transplantation activity is growing worldwide, with results comparable matched
      unrelated donors.

      The objective of this study is to test the feasibility of haploidentical transplantation with
      post transplant cyclophosphamide for acute leukemias in a Brazil.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>1-year overall survival. Survival curves will be estimated by Kaplan-Meier methodology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of leukemia relapse</measure>
    <time_frame>5 years</time_frame>
    <description>Relapse will be defined by reappearance of Leukemic Cells in bone marrow (&gt;5%) or peripheral blood (&gt;1%). Risk factors for leukemia relapse will be estimated by extended Cox Model for competing risks (Fine &amp; Gray model). Competing event will be defined as death in remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant Related Mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Transplant-related mortality (TRM) will be defined as death in remission. Risk factors for TRM will be estimated by extended Cox Model for competing risks (Fine &amp; Gray model). Competing event will be defined as leukemia relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of acute Graft Versus Host Disease</measure>
    <time_frame>5 years</time_frame>
    <description>Acute graft versus host disease will be diagnosed and graded by modified Glucksberg criteria. Risk factor for acute graft versus host disease will be estimated by extended Cox Model for competing risks (Fine &amp; Gray model). Cumulative incidence curves will be estimated by Gray methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of chronic Graft Versus Host Disease</measure>
    <time_frame>5 years</time_frame>
    <description>Chronic graft versus host disease will be diagnosed and graded by National Institute of Health Consensus (NIH Consensus). Risk factor for chronic graft versus host disease will be estimated by extended Cox Model for competing risks (Fine &amp; Gray model). Cumulative incidence curves will be estimated by Gray methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Infectious Complications</measure>
    <time_frame>1 year</time_frame>
    <description>Cumulative incidence of viral, fungal and bacterial infections. Subgroups will be compared by Cox Model for competing risks (Fine &amp; Gray model). Cytomegalovirus reactivation will be analyzed by multiple events Cox Model.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Precursor Cell Lymphoblastic Leukemia-Lymphoma</condition>
  <arm_group>
    <arm_group_label>Group A: Acute Lymphoblastic Leukemia</arm_group_label>
    <description>Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy)
Preferred conditioning:
Total Body Irradiation 1200 cGy (TBI1200) + Fludarabine 120 mg/m2 (Flu120)
Alternative conditionings:
Melphalan 100-140 mg/m2 (Mel100-140) + Fludarabine 160 mg/m2 (Flu160) + Total Body Irradiation 200 cGy (TBI200)
Busulfan 9.6 mg/kg (Bu9.6) + Fludarabine 150 mg/m2 (Flu150) + TBI200 Graft versus host disease Prophylaxis: Post-Transplant Cyclophosphamide (PTCy) + Tacrolimus (FK) or Cyclosporin (CSA) + Mycophenolate Mofetil (MMF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Acute Myeloid Leukemia</arm_group_label>
    <description>Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy) Preferred Conditioning: Mel100-140 + Flu160 + TBI200
Alternative conditionings:
Bu9,6 + Flu150 + TBI200
Cyclophosphamide 29 mg/kg + Flu150 + TBI200 Graft versus host disease Prophylaxis: PTCy + FK or CSA + MMF</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Haploidentical Stem Cell Transplantation</intervention_name>
    <description>Haploidentical Stem Cell Transplantation from a related donor (partially matched sibling, father, mother, son or daughter).</description>
    <arm_group_label>Group A: Acute Lymphoblastic Leukemia</arm_group_label>
    <arm_group_label>Group B: Acute Myeloid Leukemia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute leukemias referred for stem cell transplantation without HLA-matched
        related or unrelated donor
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute lymphoblastic leukemia or acute myeloid leukemia

        Exclusion Criteria:

          -  Severe comorbidities

          -  Second transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo J Arcuri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cancer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leonado J Arcuri, MD</last_name>
    <phone>+55(21)32071304</phone>
    <email>leonardojavier@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Nacional de Cancer</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20230-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo J Arcuri, MD</last_name>
      <phone>+55(21)3207-1304</phone>
      <email>leonardojavier@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Simone Lermontov</last_name>
      <phone>+55(21)3207-1261</phone>
      <email>simonelermontov@globo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancer, Brazil</investigator_affiliation>
    <investigator_full_name>Leonardo Javier Arcuri</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Haploidentical Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Partially Matched Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Post-transplant Cyclophosphamide</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

